CD8A and neoplasm: In particular, about 60% of MSS CRCs have an up-regulation of the MAP-kinase pathway, which leads to a reduction of Major Histocompatibility Complex (MHC) class I molecules’ expression and a decrease of the number of CD8-positive T cells in the tumor core (12).